Lucid Diagnostics Inc.

NASDAQ:LUCD

0.95 (USD) • At close February 5, 2025
Bedrijfsnaam Lucid Diagnostics Inc.
Symbool LUCD
Munteenheid USD
Prijs 0.95
Beurswaarde 56,357,553
Dividendpercentage 0%
52-weken bereik 0.63 - 1.4
Industrie Medical Devices
Sector Healthcare
CEO Dr. Lishan Aklog M.D.
Website https://www.luciddx.com

An error occurred while fetching data.

Over Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products

Vergelijkbare Aandelen

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

1.01 USD

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO

0.693 USD

Adverum Biotechnologies, Inc. logo

Adverum Biotechnologies, Inc.

ADVM

4.52 USD

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

14.33 USD

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

ALZN

1.19 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

1.91 USD

Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc.

PBYI

2.93 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)